432 related articles for article (PubMed ID: 18272483)
1. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy.
Orengo JP; Chambon P; Metzger D; Mosier DR; Snipes GJ; Cooper TA
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2646-51. PubMed ID: 18272483
[TBL] [Abstract][Full Text] [Related]
2. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
[TBL] [Abstract][Full Text] [Related]
3. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
[TBL] [Abstract][Full Text] [Related]
4. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
[TBL] [Abstract][Full Text] [Related]
5. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry analysis of complexes formed by myotonic dystrophy protein kinase (DMPK).
Forner F; Furlan S; Salvatori S
Biochim Biophys Acta; 2010 Jun; 1804(6):1334-41. PubMed ID: 20188867
[TBL] [Abstract][Full Text] [Related]
7. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.
Koshelev M; Sarma S; Price RE; Wehrens XH; Cooper TA
Hum Mol Genet; 2010 Mar; 19(6):1066-75. PubMed ID: 20051426
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
Morriss GR; Rajapakshe K; Huang S; Coarfa C; Cooper TA
Hum Mol Genet; 2018 Aug; 27(16):2789-2804. PubMed ID: 29771332
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
10. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
11. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.
Kuyumcu-Martinez NM; Wang GS; Cooper TA
Mol Cell; 2007 Oct; 28(1):68-78. PubMed ID: 17936705
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features.
Dansithong W; Wolf CM; Sarkar P; Paul S; Chiang A; Holt I; Morris GE; Branco D; Sherwood MC; Comai L; Berul CI; Reddy S
PLoS One; 2008; 3(12):e3968. PubMed ID: 19092997
[TBL] [Abstract][Full Text] [Related]
14. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.
Wang GS; Kuyumcu-Martinez MN; Sarma S; Mathur N; Wehrens XH; Cooper TA
J Clin Invest; 2009 Dec; 119(12):3797-806. PubMed ID: 19907076
[TBL] [Abstract][Full Text] [Related]
15. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
[TBL] [Abstract][Full Text] [Related]
16. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
17. Myotonic dystrophy: the role of the CUG triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic DMPK mRNA isoform ratios.
Tiscornia G; Mahadevan MS
Mol Cell; 2000 Jun; 5(6):959-67. PubMed ID: 10911990
[TBL] [Abstract][Full Text] [Related]
18. MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.
Yadava RS; Kim YK; Mandal M; Mahadevan K; Gladman JT; Yu Q; Mahadevan MS
Hum Mol Genet; 2019 Jul; 28(14):2330-2338. PubMed ID: 30997488
[TBL] [Abstract][Full Text] [Related]
19. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
[TBL] [Abstract][Full Text] [Related]
20. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.
Mahadevan MS; Yadava RS; Yu Q; Balijepalli S; Frenzel-McCardell CD; Bourne TD; Phillips LH
Nat Genet; 2006 Sep; 38(9):1066-70. PubMed ID: 16878132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
